Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Foradil, Spiriva Labeling Will Be Revised To Highlight "For Inhalation Only"

This article was originally published in The Pink Sheet Daily

Executive Summary

Crowded labeling on unit-dose packages of Schering's Foradil Aerolizer and Pfizer/Boehringer's Spiriva HandiHaler fail to prominently highlight the capsules are for inhalation use. FDA is advising health care workers to warn patients against accidentally swallowing the asthma/COPD products after 30 cases of misadministration.

You may also be interested in...



Schering Foradil Detail Aid Implies Overly Broad Asthma Claim, FDA Says

Marketing material also "fails to reveal important risk information" about the bronchodilator, the ad division letter states. Schering says the aid was used for a specific managed care audience and was discontinued earlier in the year.

India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs

Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.

Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight

Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel